{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Direct+Oral+Anticoagulants+%28DOAC%29",
    "query": {
      "intervention": "Direct Oral Anticoagulants (DOAC)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Direct+Oral+Anticoagulants+%28DOAC%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T09:16:52.072Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04979780",
      "title": "Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Treatment of Venous Thromboembolism in Cancer Patients",
        "Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Low molecular weight heparin (LMWH)",
          "type": "DRUG"
        },
        {
          "name": "Direct Oral Anticoagulants (DOAC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3708,
      "start_date": "2021-07-20",
      "completion_date": "2022-03-31",
      "has_results": false,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-10-01T09:16:52.072Z",
      "location_count": 1,
      "location_summary": "Multiple Locations, Connecticut",
      "locations": [
        {
          "city": "Multiple Locations",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04979780"
    },
    {
      "nct_id": "NCT04247919",
      "title": "DOAC ADRs Retrospective Study",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Drug-Related Side Effects and Adverse Reactions"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Cipherome, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 3,
      "start_date": "2020-01-10",
      "completion_date": "2020-07-24",
      "has_results": false,
      "last_update_posted_date": "2021-03-08",
      "last_synced_at": "2026-10-01T09:16:52.072Z",
      "location_count": 1,
      "location_summary": "San Jose, California",
      "locations": [
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04247919"
    },
    {
      "nct_id": "NCT06232551",
      "title": "Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Venous Thromboembolic Disease",
        "Pulmonary Embolism and Thrombosis",
        "Deep Vein Thrombosis",
        "Hospitalism"
      ],
      "interventions": [
        {
          "name": "EHR (electronic health record) alert",
          "type": "OTHER"
        },
        {
          "name": "No EHR (electronic health record) alert",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Scott C. Woller, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 152000,
      "start_date": "2024-06-01",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2024-07-17",
      "last_synced_at": "2026-10-01T09:16:52.072Z",
      "location_count": 1,
      "location_summary": "Murray, Utah",
      "locations": [
        {
          "city": "Murray",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06232551"
    },
    {
      "nct_id": "NCT07012291",
      "title": "Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coagulation"
      ],
      "interventions": [
        {
          "name": "Whole Blood Clotting Time",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Perosphere Technologies Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 150,
      "start_date": "2025-06-20",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-10-01T09:16:52.072Z",
      "location_count": 4,
      "location_summary": "Danbury, Connecticut • Rockville, Maryland • Denville, New Jersey + 1 more",
      "locations": [
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Denville",
          "state": "New Jersey"
        },
        {
          "city": "Cooperstown",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07012291"
    },
    {
      "nct_id": "NCT04394234",
      "title": "A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Uterine Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Direct oral anticoagulant (DOACs)",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 961985,
      "start_date": "2020-05-15",
      "completion_date": "2020-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-10-01T09:16:52.072Z",
      "location_count": 1,
      "location_summary": "Titusville, New Jersey",
      "locations": [
        {
          "city": "Titusville",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04394234"
    },
    {
      "nct_id": "NCT02666742",
      "title": "DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ventricular Tachycardia",
        "Premature Ventricular Contraction",
        "Stroke"
      ],
      "interventions": [
        {
          "name": "DOAC",
          "type": "DRUG"
        },
        {
          "name": "Aspirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kansas City Heart Rhythm Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 246,
      "start_date": "2017-02-16",
      "completion_date": "2021-04-30",
      "has_results": true,
      "last_update_posted_date": "2022-08-22",
      "last_synced_at": "2026-10-01T09:16:52.072Z",
      "location_count": 4,
      "location_summary": "Kansas City, Kansas • Overland Park, Kansas • The Bronx, New York + 1 more",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02666742"
    },
    {
      "nct_id": "NCT07621796",
      "title": "Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Intravenous tenecteplase (TNK)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hackensack Meridian Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 660,
      "start_date": "2027-01-01",
      "completion_date": "2032-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-10-01T09:16:52.072Z",
      "location_count": 1,
      "location_summary": "Neptune City, New Jersey",
      "locations": [
        {
          "city": "Neptune City",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07621796"
    },
    {
      "nct_id": "NCT06957366",
      "title": "Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Atrial Fibrillation (AF)",
        "VTE"
      ],
      "interventions": [
        {
          "name": "PAUSE Perioperative DOAC Management",
          "type": "OTHER"
        },
        {
          "name": "ASRA Perioperative DOAC Management",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "McMaster University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 920,
      "start_date": "2025-04-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-09",
      "last_synced_at": "2026-10-01T09:16:52.072Z",
      "location_count": 6,
      "location_summary": "Hartford, Connecticut • Evanston, Illinois • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06957366"
    },
    {
      "nct_id": "NCT05498428",
      "title": "A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Amivantamab",
          "type": "DRUG"
        },
        {
          "name": "Lazertinib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Direct Oral Anticoagulant (DOAC)",
          "type": "DRUG"
        },
        {
          "name": "Low Molecular Weight Heparin (LMWH)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 520,
      "start_date": "2022-11-11",
      "completion_date": "2028-08-18",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-01T09:16:52.072Z",
      "location_count": 26,
      "location_summary": "La Jolla, California • Orange, California • Stanford, California + 21 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05498428"
    },
    {
      "nct_id": "NCT04068727",
      "title": "LEAVE Safe With DOACs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Venous Thromboembolism",
        "Atrial Fibrillation",
        "Bleeding",
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Clinical Pharmacist Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 561,
      "start_date": "2019-12-02",
      "completion_date": "2022-09-14",
      "has_results": false,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-10-01T09:16:52.072Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04068727"
    }
  ]
}